The remarkable advances in immunotherapy, with response rates rarely reached so far in some diseases such as cancers, are facing unexpected challenges in predicting which patients will benefit from these immunotherapies, develop immune-related adverse events or relapse. At the era of personalized medicine, it has become a top priority to identify and characterize factors that will allow early diagnosis and therapeutic intervention, early prediction of response or relapse to disease-modifying therapies in pathologies such as cancer, autoimmune or inflammatory diseases, neurodegenerative disorders.
Multiplexing technologies such as Luminex or Cira Immunoassay technology, or ultra-sensitive platforms, such as the SIMOA™ (Quanterix) or Erenna™ (Singulex), offer deeper characterization of the complexity and dynamics of circulating biomarkers early in the pathogenesis process.
As an expert in immunoassay development and validation, ABL offers:
If your research project includes the detection and monitoring of soluble biomarkers, don’t hesitate to contact usContact us